IGF-1 DES

825 upregulated and 1300 downregulated transcripts were common in both beef breeds compared to dairy breed.; The largest group of differentially expressed genes was involved in muscle organ development.; Beef breeds had higher expression of myogenesis genes (e.g., erbb-3, myf5, myog, des, igf-1, tgfb2) and contractile apparatus genes (e.g., acta1, myh3, myl1, tnnt2).; The expression profile of proliferating satellite cells is shared among beef breeds but distinct from dairy breeds.

Vitamin D inhibits the RhoA/ROCK pathway and reduces cyclooxygenase-2 expression and prostaglandin E2 production in BPH stromal cells.; Higher dietary and supplemental vitamin D intake is associated with lower BPH prevalence.; Vitamin D analogues up to 6000 IU/day decreased prostate volume in BPH patients.; Pre-clinical trials showed vitamin D reduces BPH cell proliferation, even when induced by growth promoters like testosterone and IL-8.

Free IGF-1 levels were significantly greater in post-RYGB patients (2.55 ± 1.54 µg/L) than in pre-RYGB obese patients (1.32 ± 0.65 µg/L, P = .03) and similar to normal-weight controls (2.54 ± 1.27 µg/L).; Necdin and E2F4 gene expression in adipose tissue was significantly downregulated after RYGB compared with obese patients and similar to control levels.; In mature human adipocytes cultured in vitro, des-IGF-1 treatment induced dose-dependent downregulation of necdin and E2F4 gene expression (P = .01).; The insulin/IGF-1 signaling pathway is activated after RYGB and may account for decreased necdin expression, potentially representing a mechanism for resolution of insulin resistance after RYGB.

IGF-1(des) expression caused hyperplastic prostate growth in all transgenic mice.; Well-differentiated hyperplastic lesions did not progress to adenocarcinoma within one year.; Crossing PB-Des mice with a prostate cancer model delayed organ-confined tumor progression and metastasis in young mice.; IGF-1(des) was absent in poorly differentiated primary tumors and metastases, indicating negative selection against IGF-1 action.

Des-IGF-1 (40 ng/ml) increased fEPSP slope by 40% in CA1 region.; Enhancement was postsynaptic and mediated by AMPA, not NMDA, receptors.; Effect was blocked by genistein and significantly reduced by PI3K inhibitors wortmannin and LY294002.; Acute des-IGF-1 action may contribute to cognitive improvement via AMPA receptor modulation.

BMP-2 decreases myogenin protein stability, reducing its half-life to 50% independently of mRNA levels; Proteasome inhibitors abolish BMP-2-induced myogenin degradation; Forced Id1 expression causes myogenin degradation even in the absence of BMP-2; E47 overexpression blocks BMP-2's inhibitory effect and stabilizes myogenin through helix-loop-helix heterodimerization

des-IGF-1 upregulated TNF alpha-induced IL-8 expression at protein, mRNA, and hnRNA levels; Upregulation involved RNA transcription, not RNA stabilization; des-IGF-1 partly inhibited TNF alpha-induced NF-kappa B activation and I kappa B alpha degradation through a PI-3K-dependent pathway; A C/EBP site cooperating with a NF-kappa B site on the IL-8 enhancer contributed to upregulation, with loss of C/EBP alpha binding in IGF-1-treated cells

Type 1 IGF receptor immunoreactivity increased ~3-fold in INL and GCL of diabetic rats vs controls.; Phospho-Akt (Thr 308) immunoreactivity increased 5-fold in GCL and 8-fold in INL of diabetic rats.; Des(1-3)IGF-1 treatment significantly reduced immunoreactive cells in both layers.; Preliminary results suggested VEGF levels may also be reduced by the treatment.

What is IGF-1 DES?

IGF-1 DES (DES(1-3) IGF-1) is a naturally occurring truncated variant of insulin-like growth factor 1, lacking the N-terminal tripeptide Gly-Pro-Glu. This deletion reduces its affinity for IGF-binding proteins (IGFBPs), resulting in a significantly shorter half-life but enhanced local bioavailability and potency at the

How does IGF-1 DES work?

Truncated IGF-1 variant with high local potency and short half-life, studied for site-specific muscle growth.

What is the research status of IGF-1 DES?

IGF-1 DES is currently classified as preclinical, with 29 research references on record. This is for research purposes only and is not medical advice.